Overview

Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research

Status:
RECRUITING
Trial end date:
2027-10-15
Target enrollment:
Participant gender:
Summary
A Study of Metabolically Armed BCMA CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Plasma Cell Neoplasms.
Phase:
EARLY_PHASE1
Details
Lead Sponsor:
Anhui Provincial Hospital
Collaborator:
Leman Biotech Co., Ltd.